COPD Symptoms in the Morning: Impact, Evaluation and Management

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2013 Oct 23

PMID 24143997

Citations 44

Authors

Nicolas Roche

Niels H Chavannes

Marc Miravitlles

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) symptoms in the morning, including dyspnea and sputum production, affect patients' quality of life and limit their ability to carry out even simple morning activities. It is now emerging that these symptoms are associated with increased risk of exacerbations and work absenteeism, suggesting that they have a more profound impact on patients than previously thought. The development of validated patient-reported outcome (PRO) questionnaires to capture patients' experience of COPD symptoms in the morning is, therefore, vital for establishing effective and comprehensive management strategies. Although it is well established that long-acting bronchodilators are effective in improving COPD symptoms, the limited available data on their impact on morning symptoms and activities have been obtained with non-validated PRO questionnaires. In this review, we discuss the impact of COPD symptoms in the morning and available tools used to evaluate them, and highlight specific gaps that need to be addressed to develop standardized instruments able to meet regulatory requirement. We also present available evidence on the effect of pharmacological therapies on morning symptoms.

Citing Articles

Therapeutic efficacy and pharmacological mechanism of Bailing capsule on chronic obstructive pulmonary disease: a meta-analysis and network pharmacology.

Ma G, Jin Y Pharm Biol. 2024; 62(1):803-817.

PMID: 39460586 PMC: 11514402. DOI: 10.1080/13880209.2024.2415643.

AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries.

Sivapalan P, Romer V, Klausen T, Johansen N, Pareek M, Modin D Front Med (Lausanne). 2024; 11:1430169.

PMID: 39165373 PMC: 11334606. DOI: 10.3389/fmed.2024.1430169.

Exercise training influence on cognitive capacity and mental health within chronic obstructive pulmonary disease - A pilot study.

Hong C, Shen Y, Chang E, Hou H, Chen Y Tzu Chi Med J. 2024; 36(2):188-194.

PMID: 38645787 PMC: 11025594. DOI: 10.4103/tcmj.tcmj_128_23.

[Delphi Consensus of Argentine Pulmonologists on the Management of Patients with COPD in Real Life].

Penizzotto M, Lopez A, Wustten C, Abratte V, Arias S Open Respir Arch. 2024; 6(2):100302.

PMID: 38444983 PMC: 10912902. DOI: 10.1016/j.opresp.2024.100302.

Circadian disruption in lung fibroblasts enhances NF-κB activity to exacerbate neutrophil recruitment.

Cox S, OSiorain J, He Y, Lordan R, Naik A, Tang S FASEB J. 2023; 37(2):e22753.

PMID: 36624683 PMC: 10107448. DOI: 10.1096/fj.202201456R.

References

Dahl R, Chung K, Buhl R, Magnussen H, Nonikov V, Jack D . Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65(6):473-9. DOI: 10.1136/thx.2009.125435. View

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Partridge M, Schuermann W, Beckman O, Persson T, Polanowski T . Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis. 2009; 3(4):1-11. DOI: 10.1177/1753465809344870. View

Kessler R, Partridge M, Miravitlles M, Cazzola M, Vogelmeier C, Leynaud D . Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2010; 37(2):264-72. DOI: 10.1183/09031936.00051110. View

Dahl R, Greefhorst L, Nowak D, Nonikov V, Byrne A, Thomson M . Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 164(5):778-84. DOI: 10.1164/ajrccm.164.5.2007006. View

Beier J, Kirsten A, Mroz R, Segarra R, Chuecos F, Caracta C . Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10(4):511-22. PMC: 3787813. DOI: 10.3109/15412555.2013.814626. View

Cazzola M, Molimard M . The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010; 23(4):257-67. DOI: 10.1016/j.pupt.2010.03.003. View

McCarley C, Hanneman S, Padhye N, Smolensky M . A pilot home study of temporal variations of symptoms in chronic obstructive lung disease. Biol Res Nurs. 2007; 9(1):8-20. DOI: 10.1177/1099800407303501. View

Miravitlles M, Llor C, de Castellar R, Izquierdo I, Baro E, Donado E . Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J. 2009; 33(3):519-27. DOI: 10.1183/09031936.00087208. View

10.

Reishtein J . Relationship between symptoms and functional performance in COPD. Res Nurs Health. 2004; 28(1):39-47. DOI: 10.1002/nur.20054. View

11.

Kerwin E, DUrzo A, Gelb A, Lakkis H, Garcia Gil E, Caracta C . Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9(2):90-101. DOI: 10.3109/15412555.2012.661492. View

12.

ODonnell D, Laveneziana P . The clinical importance of dynamic lung hyperinflation in COPD. COPD. 2007; 3(4):219-32. DOI: 10.1080/15412550600977478. View

13.

Kinsman R, Yaroush R, Fernandez E, Dirks J, Schocket M, Fukuhara J . Symptoms and experiences in chronic bronchitis and emphysema. Chest. 1983; 83(5):755-61. DOI: 10.1378/chest.83.5.755. View

14.

Laveneziana P, Parker C, ODonnell D . Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Appl Physiol Nutr Metab. 2007; 32(6):1225-38. DOI: 10.1139/H07-119. View

15.

DUrzo A, Ferguson G, van Noord J, Hirata K, Martin C, Horton R . Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res. 2011; 12:156. PMC: 3266210. DOI: 10.1186/1465-9921-12-156. View

16.

Calverley P, Lee A, Towse L, van Noord J, Witek T, Kelsen S . Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax. 2003; 58(10):855-60. PMC: 1746483. DOI: 10.1136/thorax.58.10.855. View

17.

Vogelmeier C, Verkindre C, Cheung D, Galdiz J, Guclu S, Spangenthal S . Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther. 2010; 23(5):438-44. DOI: 10.1016/j.pupt.2010.04.005. View

18.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C . Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2010; 37(2):273-9. DOI: 10.1183/09031936.00045810. View

19.

Kuyucu T, Guclu S, Saylan B, Demir C, Senol T, Guner S . A cross-sectional observational study to investigate daily symptom variability, effects of symptom on morning activities and therapeutic expectations of patients and physicians in COPD-SUNRISE study. Tuberk Toraks. 2012; 59(4):328-39. DOI: 10.5578/tt.3268. View

20.

Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl C . Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006; 130(1):133-42. DOI: 10.1378/chest.130.1.133. View